Piramal Pharma Limited
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitionsand various organic…
What Piramal files
- Others47
- Investor Meet43
- Important30
- Updates25
- Board Meeting11
- PPTs8
Piramal Pharma received an improved ESG rating of 65 for FY26 from NSE Sustainability, up from 64. This highlights the company's ongoing commitment to sustainability and responsible operations.
Piramal Pharma reported Q1 FY27 revenue up 17% to ₹2,270 Cr, and EBITDA surged 72% to ₹285 Cr (12.5% margin). Growth across all segments with improved execution. CDMO strong, CHG gained ex-US traction, PCH boosted by Power Brands.
Piramal Pharma's committee approved granting 0.56 Cr employee stock options at ₹10 each under its Plan 2022. These options vest over three years, aiming to incentivize employees and link rewards to performance.
Piramal Pharma's Sellersville (USA) facility successfully closed its US FDA inspection, with an Establishment Inspection Report issued. This positive news ensures continued market access and operational stability for the facility.
Piramal Pharma's Digwal facility inspection is successfully closed by the US FDA, following the issuance of an Establishment Inspection Report (EIR). This is a positive operational development, removing regulatory uncertainty for the company's US market supplies.